Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 584504, 7 pages
http://dx.doi.org/10.1155/2013/584504
Research Article

Soluble RAGE Plasma Levels in Patients with Coronary Artery Disease and Peripheral Artery Disease

1Interdepartmental Center of Research in Molecular Medicine (CIRMC), University of Pavia, 27100 Pavia, Italy
2Department of Cardiology, “Istituti Clinici di Pavia e Vigevano” University Hospital, 27100 Pavia, Italy
3IRCCS San Donato Hospital, San Donato Milanese, 20097 Milan, Italy
4Department of Internal Medicine, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
5Department of Clinical and Experimental Medicine, University of Insubria, 21100 Varese, Italy
6Department of Vascular Surgery, “Istituti Clinici di Pavia e Vigevano”, University Hospital, 27100 Pavia, Italy

Received 20 August 2013; Accepted 12 September 2013

Academic Editors: P. Ferroni and S. Ueda

Copyright © 2013 Colomba Falcone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Congiu, L. Schembri, M. Tozzi et al., “Scanning electron microscopy examination of endothelium morphology in human carotid plaques,” Micron, vol. 41, no. 5, pp. 532–536, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. D. A. Stehouwer, D. Clement, C. Davidson et al., “Peripheral arterial disease: a growing problem for the internist,” European Journal of Internal Medicine, vol. 20, no. 2, pp. 132–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Sukhija, W. S. Aronow, K. Yalamanchili, N. Sinha, and S. Babu, “Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm,” American Journal of Cardiology, vol. 94, no. 10, pp. 1358–1359, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. R. S. Dieter, J. Tomasson, T. Gudjonsson et al., “Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease,” Vascular Medicine, vol. 8, no. 4, pp. 233–236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. E. T. Fung, A. M. Wilson, F. Zhang et al., “A biomarker panel for peripheral arterial disease,” Vascular Medicine, vol. 13, no. 3, pp. 217–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Guasti, F. Marino, M. Cosentino et al., “Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study,” Journal of Hypertension, vol. 24, no. 12, pp. 2423–2430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Marino, L. Guasti, M. Cosentino et al., “Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes,” Journal of Hypertension, vol. 26, no. 6, pp. 1147–1155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Guasti, F. Marino, M. Cosentino et al., “Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-Year follow-up,” European Heart Journal, vol. 29, no. 9, pp. 1118–1126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Marino, L. Guasti, M. Cosentino et al., “Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin,” Journal of Cardiovascular Pharmacology, vol. 49, no. 5, pp. 299–305, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Marino, L. Guasti, M. Tozzi et al., “Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease,” Journal of Cardiovascular Pharmacology, vol. 54, no. 6, pp. 520–525, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Marino, A. M. Maresca, M. Cosentino et al., “Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment,” Cardiovascular Diabetology, vol. 11, article 153, 2012. View at Publisher · View at Google Scholar
  12. D. P. Faxon, V. Fuster, P. Libby et al., “Atherosclerotic vascular disease conference. Writing group III: pathophysiology,” Circulation, vol. 109, no. 21, pp. 2617–2625, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Falcone, E. Emanuele, A. D'Angelo et al., “Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 5, pp. 1032–1037, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Falcone, M. P. Buzzi, S. Bozzini et al., “TALENT Investigators. Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk,” Journal of Nephrology, vol. 26, no. 1, pp. 144–151, 2013. View at Publisher · View at Google Scholar
  15. D. Geroldi, C. Falcone, E. Emanuele et al., “Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension,” Journal of Hypertension, vol. 23, no. 9, pp. 1725–1729, 2005. View at Google Scholar · View at Scopus
  16. A. Raucci, S. Cugusi, A. Antonelli et al., “A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10),” FASEB Journal, vol. 22, no. 10, pp. 3716–3727, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. T. Hirsch, Z. J. Haskal, N. R. Hertzer et al., “ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology,,” Circulation, vol. 113, no. 11, pp. e463–654, 2006. View at Google Scholar · View at Scopus
  18. U. Zeymer, K. G. Parhofer, D. Pittrow et al., “Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort,” Clinical Research in Cardiology, vol. 98, no. 4, pp. 249–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. I. D. Moussa, M. R. Jaff, R. Mehran et al., “Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the peripheral arterial disease in interventional patients study,” Catheterization and Cardiovascular Interventions, vol. 73, no. 6, pp. 719–724, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American heart association,” Circulation, vol. 125, no. 1, pp. e2–e220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Steg, D. L. Bhatt, P. W. F. Wilson et al., “One-year cardiovascular event rates in outpatients with atherothrombosis,” Journal of the American Medical Association, vol. 297, no. 11, pp. 1197–1206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Brevetti, G. Giugliano, L. Brevetti, and W. R. Hiatt, “Inflammation in peripheral artery disease,” Circulation, vol. 122, no. 18, pp. 1862–1875, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. B. Lindsey, F. Cipollone, S. M. Abdullah, and D. K. McGuire, “Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications,” Diabetes and Vascular Disease Research, vol. 6, no. 1, pp. 7–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Kislinger, C. Fu, B. Huber et al., “N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression,” Journal of Biological Chemistry, vol. 274, no. 44, pp. 31740–31749, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Santilli, N. Vazzana, L. G. Bucciarelli, and G. Davì, “Soluble forms of RAGE in human diseases: clinical and therapeutical implications,” Current Medicinal Chemistry, vol. 16, no. 8, pp. 940–952, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Park, K. G. Raman, K. J. Lee et al., “Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts,” Nature Medicine, vol. 4, no. 9, pp. 1025–1031, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. M. T. Goova, J. Li, T. Kislinger et al., “Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice,” American Journal of Pathology, vol. 159, no. 2, pp. 513–525, 2001. View at Google Scholar · View at Scopus
  28. A. Taguchi, D. C. Blood, G. Del Toro et al., “Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases,” Nature, vol. 405, no. 6784, pp. 354–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Kotani, R. Caccavello, N. Taniguchi, and A. Gugliucci, “Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects,” Journal of International Medical Research, vol. 40, pp. 1878–1883, 2012. View at Publisher · View at Google Scholar
  30. N. Mahajan, N. Malik, A. Bahl, and V. Dhawan, “Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease,” Atherosclerosis, vol. 207, no. 2, pp. 597–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Mahajan, N. Malik, A. Bahl, Y. Sharma, and V. Dhawan, “Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease,” Molecular and Cellular Biochemistry, vol. 330, no. 1-2, pp. 201–209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Nakamura, S. I. Yamagishi, H. Adachi et al., “Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease,” Diabetes/Metabolism Research and Reviews, vol. 23, no. 5, pp. 368–371, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Basta, S. Del Turco, T. Navarra et al., “Inverse association between circulating levels of soluble receptor for advanced glycation end-products and coronary plaque burden,” Journal of Atherosclerosis and Thrombosis, vol. 19, pp. 941–948, 2012. View at Google Scholar
  34. H. M. Colhoun, D. J. Betteridge, P. Durrington et al., “Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial,” Diabetes, vol. 60, no. 9, pp. 2379–2385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. W. M. Nin, A. Jorsal, I. Ferreira et al., “Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study,” Diabetes, vol. 59, no. 8, pp. 2027–2032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Fujisawa, N. Katakami, H. Kaneto et al., “Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes,” Atherosclerosis, vol. 227, pp. 425–428, 2013. View at Publisher · View at Google Scholar
  37. K. H. Chiang, P. H. Huang, S. S. Huang, T. C. Wu, J. W. Chen, and S. J. Lin, “Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients,” Coronary Artery Disease, vol. 20, no. 4, pp. 267–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Selvin, M. Halushka, A. Rawlings et al., “sRAGE and risk of diabetes, cardiovascular disease and death,” Diabetes, vol. 62, no. 6, pp. 2116–2121, 2013. View at Publisher · View at Google Scholar
  39. E. D. McNair, C. R. Wells, A. Mabood Qureshi et al., “Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention,” Clinical Cardiology, vol. 33, no. 11, pp. 678–685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Fukushima, H. Daida, T. Morimoto et al., “JAPAN-ACS Investigators. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study,” Cardiovascular Diabetology, vol. 12, article 5, 2013. View at Publisher · View at Google Scholar
  41. H. Koyama, T. Shoji, H. Yokoyama et al., “Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 12, pp. 2587–2593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Katakami, M. Matsuhisa, H. Kaneto et al., “Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications,” Diabetes Care, vol. 28, no. 11, pp. 2716–2721, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Basta, A. M. Sironi, G. Lazzerini et al., “Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4628–4634, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Devangelio, F. Santilli, G. Formoso et al., “Soluble RAGE in type 2 diabetes: association with oxidative stress,” Free Radical Biology and Medicine, vol. 43, no. 4, pp. 511–518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Challier, S. Jacqueminet, O. Benabdesselam, A. Grimaldi, and J. L. Beaudeux, “Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes,” Clinical Chemistry, vol. 51, no. 9, pp. 1749–1750, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. K. C. Tan, S. W. Shiu, W. S. Chow, L. Leng, R. Bucala, and D. J. Betteridge, “Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes,” Diabetologia, vol. 49, no. 11, pp. 2756–2762, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. E. D. McNair, C. R. Wells, A. Mabood Qureshi et al., “Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products,” Molecular and Cellular Biochemistry, vol. 341, no. 1-2, pp. 135–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Kinlay, “Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein. A meta-analysis,” Journal of the American College of Cardiology, vol. 49, no. 20, pp. 2003–2009, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Yonekura, Y. Yamamoto, S. Sakurai et al., “Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury,” Biochemical Journal, vol. 370, no. 3, pp. 1097–1109, 2003. View at Publisher · View at Google Scholar · View at Scopus